MTFB has been the topic of several other reports. Peel Hunt reiterated a buy rating on shares of Motif Bio in a research note on Tuesday, July 3rd. Northland Capital Partners reiterated a buy rating on shares of Motif Bio in a research note on Monday, June 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Motif Bio presently has a consensus rating of Buy and a consensus target price of GBX 109.40 ($1.40).
Shares of Motif Bio stock opened at GBX 34.43 ($0.44) on Tuesday. Motif Bio has a 52 week low of GBX 23.50 ($0.30) and a 52 week high of GBX 51.75 ($0.66).
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Further Reading: Trading Strategy Methods and Types
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.